Senti Biosciences
Team of bioengineers, scientists, and entrepreneurs on a mission to treat the most complex and challenging diseases.
Launch date
Employees
Market cap
€12.9m
Enterprise valuation
€31m (Public information from Sep 2024)
Share price
$3.133 SNTI
South San Francisco California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenues | <1m | 2.3m | 4.3m | 2.0m | 8.9m | 23.6m |
| % growth | - | 481 % | 87 % | (54 %) | 350 % | 166 % |
| EBITDA | (22.5m) | (37.4m) | (70.6m) | (39.5m) | - | - |
| % EBITDA margin | (5703 %) | (1633 %) | (1648 %) | (1999 %) | - | - |
| Profit | (19.9m) | (55.3m) | (58.2m) | (71.1m) | (60.8m) | (57.2m) |
| % profit margin | (5041 %) | (2415 %) | (1358 %) | (3592 %) | (683 %) | (242 %) |
| EV / revenue | - | 111.8x | -0.3x | 15.7x | -3.3x | -3.8x |
| EV / EBITDA | - | -6.8x | 0.0x | -0.8x | - | - |
| R&D budget | 16.0m | 22.0m | 34.1m | 32.2m | - | - |
| R&D % of revenue | 4050 % | 958 % | 795 % | 1625 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| $105m | Series B | |
N/A | Series B | ||
* | $230m | SPAC IPO | |
* | $153m | SPAC Private Placement | |
* | $8.0m | Grant | |
| Total Funding | €292m | ||
Related Content
Recent News about Senti Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.